v3.26.1
Note 11 - Segments - Schedule of Segment Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues $ 0 $ 1,917,491
Research and Development Expense 5,135,419 4,837,798
Stock-based compensation 349,196 361,167
Total general and administrative expenses 2,975,105 2,382,577
Other income 146,366 408,850
Net loss (7,964,158) (4,894,034)
Operating Segments [Member]    
Revenues 0 1,917,491
Research and Development Expense 5,135,419 4,837,798
Personnel costs, excluding stock-based compensation 1,316,430 1,111,094
Stock-based compensation 222,486 237,465
Professional fees 1,102,801 729,570
Insurance, taxes and similar fees 214,764 219,586
Other general and administrative expenses, including IT, facilities, supplies and similar costs*** 118,624 84,862
Total general and administrative expenses 2,975,105 2,382,577
Other income 146,366 408,850
Net loss (7,964,158) (4,894,034)
Operating Segments [Member] | Dementia with Lewy bodies [Member]    
Research and Development Expense 746,745 2,157,831
Operating Segments [Member] | Frontotemporal Disorders [Member]    
Research and Development Expense 467,963 146,273
Operating Segments [Member] | Recovery After Stroke [Member]    
Research and Development Expense 308,951 252,542
Operating Segments [Member] | Other Clinical and Nonclinical [Member]    
Research and Development Expense [1] 1,031,918 675,391
Operating Segments [Member] | Personnel Costs [Member]    
Research and Development Expense 978,913 773,724
Operating Segments [Member] | Stock Based Compensation [Member]    
Research and Development Expense 126,710 123,702
Operating Segments [Member] | Other Research and Development Costs [Member]    
Research and Development Expense [2] $ 1,474,219 $ 708,335
[1] Includes early-stage clinical studies that are not indication-specific and related costs.
[2] Includes, among other things, CMC-related costs, shipping, packaging and storage costs, certain consulting costs, and other miscellaneous research development expenses.